Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group
- Author
- KENTEPOZIDIS, N1 ; KOTSAKIS, A1 ; SAMONIS, G1 ; GEORGOULIAS, V1 ; SOULTATI, A1 ; AGELAKI, S1 ; CHRISTOPHYLAKIS, Ch1 ; AGELIDOU, M1 ; CHELIS, L1 ; PAPAKOTOULAS, P1 ; VAMVAKAS, L1 ; ZAFIRIOU, Z1
[1] Hellenic Oncology Research Group (HORG), 55, Lombardou Str, 114 74 Athens, Greece - Source
Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 3, pp 605-612, 8 p ; ref : 32 ref
- CODEN
- CCPHDZ
- ISSN
- 0344-5704
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- Springer, Heidelberg
- Publication country
- Germany
- Document type
- Article
- Language
- English
- Author keyword
- Angiogenesis and endothelium Bevacizumab Cisplatin Docetaxel Non-small-cell lung cancer
- Keyword (fr)
- Angiogenèse Antiangiogénique Anticancéreux Bévacizumab Cancer du poumon Cancérologie Carcinome non petite cellule bronchopulmonaire Cisplatine Docétaxel Endothélium Essai clinique phase II Etude multicentrique Facteur croissance endothélium vasculaire Homme Néovascularisation Recherche Stade avancé Stade précoce Toxicité Traitement Tumeur maligne Anti-VEGF Agent alkylant Anticorps monoclonal Antimitotique Cancer Dérivé du taxane Pathologie de l'appareil respiratoire Pathologie des bronches Pathologie des poumons Platine II Complexe
- Keyword (en)
- Angiogenesis Antiangiogenic agent Antineoplastic agent Bevacizumab Lung cancer Cancerology non-small cell lung carcinoma Cisplatin Docetaxel Endothelium Phase II trial Multicenter study Vascular endothelium growth factor Human Neovascularization Research Advanced stage Early stage Toxicity Treatment Malignant tumor Alkylating agent Monoclonal antibody Antimitotic Cancer Taxane derivatives Respiratory disease Bronchus disease Lung disease Platinum II Complexes
- Keyword (es)
- Angiogénesis Antiangiogenico Anticanceroso Bevacizumab Cáncer del pulmón Cancerología Carcinoma no pequeňa célula bronchopulmonar Cisplatino Docetaxel Endotelio Ensayo clínico fase II Estudio multicéntrico Factor crecimiento endotelio vascular Hombre Neovascularización Investigación Estadio avanzado Estadio precoz Toxicidad Tratamiento Tumor maligno Agente alquilante Anticuerpo monoclonal Antimitótico Cáncer Taxane derivado Aparato respiratorio patología Bronquio patología Pulmón patología Platino II Complejo
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B04 Tumors / 002B04C Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B11 Pneumology / 002B11A Tumors of the respiratory system and mediastinum
- Discipline
- Pharmacological treatments Pulmonology Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27610383
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1007/s00280-012-2037-1 
https://dx.doi.org/10.1007/s00280-012-2037-1
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-012-2037-1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:198:\"Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced\/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"71\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"605\";s:8:\"\u0000*\u0000epage\";s:3:\"612\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"KENTEPOZIDIS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:11:\"KOTSAKIS, A\";i:1;s:10:\"SAMONIS, G\";i:2;s:14:\"GEORGOULIAS, V\";i:3;s:11:\"SOULTATI, A\";i:4;s:10:\"AGELAKI, S\";i:5;s:19:\"CHRISTOPHYLAKIS, Ch\";i:6;s:11:\"AGELIDOU, M\";i:7;s:9:\"CHELIS, L\";i:8;s:15:\"PAPAKOTOULAS, P\";i:9;s:11:\"VAMVAKAS, L\";i:10;s:11:\"ZAFIRIOU, Z\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:198:\"Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced\/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-012-2037-1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:198:\"Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced\/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"71\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"605\";s:8:\"\u0000*\u0000epage\";s:3:\"612\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"KENTEPOZIDIS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:11:\"KOTSAKIS, A\";i:1;s:10:\"SAMONIS, G\";i:2;s:14:\"GEORGOULIAS, V\";i:3;s:11:\"SOULTATI, A\";i:4;s:10:\"AGELAKI, S\";i:5;s:19:\"CHRISTOPHYLAKIS, Ch\";i:6;s:11:\"AGELIDOU, M\";i:7;s:9:\"CHELIS, L\";i:8;s:15:\"PAPAKOTOULAS, P\";i:9;s:11:\"VAMVAKAS, L\";i:10;s:11:\"ZAFIRIOU, Z\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:198:\"Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced\/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-012-2037-1\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-012-2037-1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:198:\"Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced\/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"71\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"605\";s:8:\"\u0000*\u0000epage\";s:3:\"612\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"KENTEPOZIDIS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:11:\"KOTSAKIS, A\";i:1;s:10:\"SAMONIS, G\";i:2;s:14:\"GEORGOULIAS, V\";i:3;s:11:\"SOULTATI, A\";i:4;s:10:\"AGELAKI, S\";i:5;s:19:\"CHRISTOPHYLAKIS, Ch\";i:6;s:11:\"AGELIDOU, M\";i:7;s:9:\"CHELIS, L\";i:8;s:15:\"PAPAKOTOULAS, P\";i:9;s:11:\"VAMVAKAS, L\";i:10;s:11:\"ZAFIRIOU, Z\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:198:\"Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced\/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-012-2037-1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:198:\"Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced\/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"71\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"605\";s:8:\"\u0000*\u0000epage\";s:3:\"612\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"KENTEPOZIDIS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:11:\"KOTSAKIS, A\";i:1;s:10:\"SAMONIS, G\";i:2;s:14:\"GEORGOULIAS, V\";i:3;s:11:\"SOULTATI, A\";i:4;s:10:\"AGELAKI, S\";i:5;s:19:\"CHRISTOPHYLAKIS, Ch\";i:6;s:11:\"AGELIDOU, M\";i:7;s:9:\"CHELIS, L\";i:8;s:15:\"PAPAKOTOULAS, P\";i:9;s:11:\"VAMVAKAS, L\";i:10;s:11:\"ZAFIRIOU, Z\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:198:\"Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced\/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s00280-012-2037-1\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:198:\"Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced\/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group\";s:9:\"\u0000*\u0000jtitle\";s:36:\"Cancer chemotherapy and pharmacology\";s:9:\"\u0000*\u0000stitle\";s:27:\"Cancer chemother. pharmacol\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"71\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"605\";s:8:\"\u0000*\u0000epage\";s:3:\"612\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0344-5704\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"KENTEPOZIDIS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:11:\"KOTSAKIS, A\";i:1;s:10:\"SAMONIS, G\";i:2;s:14:\"GEORGOULIAS, V\";i:3;s:11:\"SOULTATI, A\";i:4;s:10:\"AGELAKI, S\";i:5;s:19:\"CHRISTOPHYLAKIS, Ch\";i:6;s:11:\"AGELIDOU, M\";i:7;s:9:\"CHELIS, L\";i:8;s:15:\"PAPAKOTOULAS, P\";i:9;s:11:\"VAMVAKAS, L\";i:10;s:11:\"ZAFIRIOU, Z\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CCPHDZ\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:198:\"Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced\/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group\";s:8:\"\u0000*\u0000place\";s:10:\"Heidelberg\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
